Gefitinib ('Iressa', ZD1839) for patients with advanced non-small-cell lung cancer treated in the 'Iressa' Expanded Access Programme at a single institution in Brazil

被引：0
|
作者：
Katz, A [1 ]
Smaletz, O [1 ]
Simon, SD [1 ]
Rene, GC [1 ]
Hoff, PM [1 ]
Tabacof, J [1 ]
机构：
[1] Hosp Israelita Albert Einstein, Ctr Paulista Oncol, Sao Paulo, Brazil
来源：
BRITISH JOURNAL OF CANCER | 2003年 / 89卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [31] Gefitinib ('IRESSA', ZD1839) in patients with non-small cell lung cancer (NSCLC): The Royal Marsden experience
    Maisey, NR
    Parton, M
    Harper-Wynne, C
    Sumpter, K
    Ashley, S
    Eisen, T
    O'Brien, M
    [J]. BRITISH JOURNAL OF CANCER, 2004, 91 : S15 - S15
  • [32] Activity of the epidermal growth factor receptor inhibitor gefitinib ('Iressa', ZD1839) in refractory non-small-cell lung cancer
    Parra, HS
    Cavina, R
    Zucali, P
    Campagnoli, E
    Latteri, F
    Biancofiore, G
    Abbadessa, G
    Morenghi, E
    Santoro, A
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S33 - S33
  • [33] Gefitinib ('Iressa', ZD1839) in elderly patients with progressive pretreated non-small-cell lung cancer: results from the Istituto Clinico Humanitas
    Parra, HS
    Cavina, R
    Zucali, P
    Campagnoli, E
    Latteri, F
    Biancofiore, G
    Abbadessa, G
    Morenghi, E
    Santoro, A
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S33 - S33
  • [34] New hope for patients with non-small-cell lung cancer: gefitinib ('Iressa', ZD 1839) and other innovative therapies
    Goss, G
    [J]. EJC SUPPLEMENTS, 2003, 1 (08): : 1 - 1
  • [35] Prolonged survival and clinical benefits with gefitinib ('Iressa', ZD1839) in a patient with brain metastasis from non-small-cell lung cancer
    de la Cruz, J
    Giacomi, N
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S27 - S28
  • [36] Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
    Xin-Lin Mu
    Long-Yun Li
    Xiao-Tong Zhang
    Shu-Lan Wang
    Meng-Zhao Wang
    [J]. BMC Cancer, 4
  • [37] Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
    Dudnik, Julia
    Lazarev, Irina
    Ariad, Shmuel
    Mermershtain, Wilmosh
    [J]. INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2006, 27 (02) : 40 - 41
  • [38] Activity of a specific inhibitor, gefitinib (Iressa™, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer
    Santoro, A
    Cavina, R
    Latteri, F
    Zucali, PA
    Ginanni, V
    Campagnoli, E
    Ferrari, B
    Morenghi, E
    Pedicini, V
    Roncalli, A
    Alloisio, M
    Ravasi, G
    Parral, HJS
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (01) : 33 - 37
  • [39] Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme
    Mu, XL
    Li, LY
    Zhang, XT
    Wang, SL
    Wang, MZ
    [J]. BMC CANCER, 2004, 4 (1)
  • [40] Quality-of-life benefits for a patient with non-small-cell lung cancer and brain metastases taking gefitinib ('Iressa', ZD1839)
    van Zandwijk, N
    [J]. BRITISH JOURNAL OF CANCER, 2003, 89 : S34 - S34
12345